{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=10", "query": { "intervention": "ruxolitinib", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 291, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ruxolitinib&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T10:38:55.765Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02493530", "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis", "Polycythemia Vera" ], "interventions": [ { "name": "TGR-1202", "type": "DRUG" }, { "name": "ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2015-07", "completion_date": "2024-05", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Nashville, Tennessee + 2 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02493530" }, { "nct_id": "NCT03117751", "title": "Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Lymphoblastic Lymphoma" ], "interventions": [ { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinase®", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Clofarabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Nelarabine", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Asparaginase Erwinia chrysanthemi (recombinant)-rywn", "type": "DRUG" }, { "name": "Calaspargase Pegol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 790, "start_date": "2017-03-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 7, "location_summary": "Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03117751" }, { "nct_id": "NCT04996160", "title": "Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric", "Relapsed Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tanja Andrea Gruber", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 2, "start_date": "2021-07-09", "completion_date": "2023-10-16", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04996160" }, { "nct_id": "NCT04640025", "title": "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Postlung Transplant (Bronchiolitis Obliterans)", "Chronic Graft Versus Host Disease" ], "interventions": [ { "name": "itacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-03-10", "completion_date": "2026-05-11", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 8, "location_summary": "Duarte, California • Aurora, Colorado • Fort Wayne, Indiana + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04640025" }, { "nct_id": "NCT02420717", "title": "Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Ph-Like Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Ph-Like Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": null, "sex": "ALL", "summary": "10 Years and older" }, "enrollment_count": 11, "start_date": "2015-07-15", "completion_date": "2021-01-20", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420717" }, { "nct_id": "NCT03745638", "title": "Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Ruxolitinib Cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 631, "start_date": "2018-12-20", "completion_date": "2020-12-01", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oceanside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03745638" }, { "nct_id": "NCT01693601", "title": "Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Panobinostat", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2013-01", "completion_date": "2018-05-18", "has_results": true, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01693601" }, { "nct_id": "NCT07025538", "title": "Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biomarker Analysis", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2026-04-29", "completion_date": "2028-06-22", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07025538" }, { "nct_id": "NCT02553330", "title": "A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alopecia Areata" ], "interventions": [ { "name": "Placebo Cream", "type": "DRUG" }, { "name": "Ruxolitinib Phosphate Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2015-11-18", "completion_date": "2017-10-03", "has_results": true, "last_update_posted_date": "2020-12-16", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Hot Springs, Arkansas • New Haven, Connecticut + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553330" }, { "nct_id": "NCT04278404", "title": "Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronavirus Infection (COVID-19)", "Pulmonary Arterial Hypertension", "Urinary Tract Infections in Children", "Hypertension", "Pain", "Hyperphosphatemia", "Primary Hyperaldosteronism", "Edema", "Hypokalemia", "Heart Failure", "Hemophilia", "Menorrhagia", "Insomnia", "Pneumonia", "Skin Infection", "Arrythmia", "Asthma in Children", "Bronchopulmonary Dysplasia", "Adrenal Insufficiency", "Fibrinolysis; Hemorrhage", "Attention Deficit Hyperactivity Disorder", "Multisystem Inflammatory Syndrome in Children (MIS-C)", "Kawasaki Disease", "Coagulation Disorder", "Down Syndrome" ], "interventions": [ { "name": "The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "0 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "0 Years to 20 Years" }, "enrollment_count": 5000, "start_date": "2020-03-05", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-17T10:38:55.765Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278404" } ] }